Standard BioTools to Participate in Upcoming Investor Conferences

FLDM 10.31.2024

Full Press ReleaseSEC FilingsOur FLDM Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
  • 01.08.2025 - Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 11.21.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

SOUTH SAN FRANCISCO, Calif.,Oct. 31, 2024(GLOBE NEWSWIRE) --Standard BioTools Inc.(NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November:

  • UBS Global Healthcare ConferenceonNovember 12th, 2024President and CEO,Michael Egholm, PhD, will participate in a corporate presentation onTuesday, November 12, 2024, at1:15 p.m. PT
  • Jefferies London Healthcare ConferenceonNovember 19th– 21st, 2024President and CEO,Michael Egholm, PhD, will participate in a corporate presentation onTuesday, November 19, 2024, at8:30 a.m. GMT

Available presentations will be webcast live and available on the Investor Relations page of the Company’s website atEvents & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page atinvestors.standardbio.com.

AboutStandard BioTools Inc.

Standard BioTools Inc.(Nasdaq: LAB), the parent company ofSomaLogic Inc.and previously known asFluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes.Standard BioToolsworks with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more atstandardbio.comor connect with us on X, Facebook®, LinkedIn, and YouTubeTM.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply:standardbio.com/legal/salesterms.Patent and License Information:standardbio.com/legal/notices.Trademarks:standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024Standard BioTools Inc.(f.k.a.Fluidigm Corporation). All rights reserved.

Investor Contact

David HolmesGilmartin Group LLCir@standardbio.com

Primary Logo

Source: Standard BioTools Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com